INDO US BIOTECH
|
INDO US BIOTECH Last 5 Year Financial Ratios History
[Standalone]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 6.54 | 8.11 | 4.12 | 7.22 | 5.71 |
| CEPS(Rs) | 6.99 | 8.66 | 4.51 | 4.02 | 3.09 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 46.15 | 39.16 | 31.29 | 54.35 | 42.41 |
| Tax Rate(%) | 5.73 | 1.59 | 6.28 | 1.98 | 4.60 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 15.41 | 18.24 | 14.83 | 15.21 | 13.85 |
| EBIT Margin(%) | 14.64 | 17.35 | 14.17 | 13.91 | 13.37 |
| Pre Tax Margin(%) | 12.60 | 15.92 | 12.09 | 11.96 | 10.97 |
| PAT Margin (%) | 11.88 | 15.67 | 11.33 | 11.73 | 10.46 |
| Cash Profit Margin (%) | 12.70 | 16.72 | 12.43 | 13.06 | 11.31 |
| Performance Ratios | |||||
| ROA(%) | 11.42 | 17.98 | 10.81 | 11.67 | 10.63 |
| ROE(%) | 15.34 | 23.03 | 14.08 | 15.51 | 17.34 |
| ROCE(%) | 14.51 | 21.15 | 14.42 | 14.62 | 15.86 |
| Asset Turnover(x) | 0.96 | 1.15 | 0.95 | 1.00 | 1.02 |
| Sales/Fixed Asset(x) | 8.58 | 9.79 | 10.36 | 9.57 | 12.72 |
| Working Capital/Sales(x) | 1.36 | 1.48 | 1.31 | 1.30 | 1.44 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.12 | 0.10 | 0.10 | 0.10 | 0.08 |
| Receivable days | 47.52 | 59.84 | 109.71 | 133.85 | 164.93 |
| Inventory Days | 281.98 | 215.16 | 197.06 | 148.59 | 128.48 |
| Payable days | 148.07 | 592.15 | -53.89 | 302.49 | -222.52 |
| Valuation Parameters | |||||
| PER(x) | 14.96 | 18.15 | 53.94 | 14.71 | 5.91 |
| PCE(x) | 14.00 | 17.00 | 49.17 | 26.41 | 10.93 |
| Price/Book(x) | 2.12 | 3.76 | 7.09 | 3.91 | 1.59 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 2.06 | 2.98 | 6.29 | 3.64 | 1.48 |
| EV/Core EBITDA(x) | 13.31 | 16.21 | 41.20 | 23.84 | 10.45 |
| EV/EBIT(x) | 14.05 | 17.19 | 44.39 | 26.14 | 11.11 |
| EV/CE(x) | 1.75 | 3.32 | 5.95 | 3.40 | 1.35 |
| M Cap / Sales | 1.78 | 2.84 | 6.11 | 3.45 | 1.24 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 6.36 | 42.56 | 17.96 | 23.36 | 24.86 |
| Core EBITDA Growth(%) | -10.70 | 71.86 | 18.17 | 32.33 | 28.02 |
| EBIT Growth(%) | -10.27 | 74.56 | 20.21 | 28.35 | 26.10 |
| PAT Growth(%) | -19.33 | 97.15 | 13.96 | 38.25 | 2.73 |
| EPS Growth(%) | -19.33 | 97.15 | -43.02 | 26.40 | -31.99 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.40 | 0.19 | 0.23 | 0.21 | 0.32 |
| Current Ratio(x) | 3.05 | 5.31 | 4.19 | 4.87 | 3.85 |
| Quick Ratio(x) | 0.52 | 0.98 | 1.22 | 2.68 | 1.94 |
| Interest Cover(x) | 7.19 | 12.09 | 6.79 | 7.15 | 5.57 |
| Total Debt/Mcap(x) | 0.19 | 0.05 | 0.03 | 0.05 | 0.20 |
Compare Financial Ratios of peers of INDO US BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDO US BIOTECH | ₹133.2 Cr | -23.3% | -13.9% | -50.6% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹3,440.5 Cr | -4.6% | -6.5% | -36.3% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,193.3 Cr | -1.3% | -3.1% | 5.4% | Stock Analytics | |
| AVT NATURAL PRODUCTS | ₹1,475.9 Cr | 5.9% | 10.3% | 37.7% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹877.9 Cr | -0.6% | -1.6% | NA | Stock Analytics | |
| MANGALAM GLOBAL ENTERPRISE | ₹565.2 Cr | -3.8% | 11.8% | 14.5% | Stock Analytics | |
INDO US BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDO US BIOTECH | -23.3% |
-13.9% |
-50.6% |
| SENSEX | 4.5% |
6.1% |
-9.3% |
You may also like the below Video Courses
